Extension study of linsitinib for thyroid eye disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests two doses of an oral medication (linsitinib) for people with active, moderate-to-severe thyroid eye disease who were in a previous study and didn't improve enough or had their bulging come back. It aims to see if continuing treatment can help with eye bulging and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the 24-week treatment in a previous thyroid eye disease study (VGN-TED-301) without enough improvement in eye bulging (less than 2 mm), or your bulging got better but then came back during the follow-up period.
- You have not had any other treatments for thyroid eye disease since that 24-week mark.
- Your thyroid levels are stable (or only mildly off – less than 50% above or below normal).
- You do not need immediate eye surgery, radiation, or other eye procedures at this time and don't plan them during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill (linsitinib) for people with active thyroid eye disease. Participation may help reduce eye bulging and other symptoms, especially if other treatments haven't worked.
This study tests a new medication (NTB003) for people with thyroid eye disease (TED), a condition that can cause bulging eyes, double vision, and discomfort. It aims to see if the treatment is safe and helps reduce symptoms.
This trial tests a new medicine (KHN939) for people with moderate-to-severe active thyroid eye disease. If you qualify, the study may help reduce bulging eyes and double vision.
This study tests an investigational drug, KHN939, for people with moderate-to-severe inactive thyroid eye disease (also called Graves' eye disease). The goal is to see if the drug can improve symptoms such as bulging eyes and double vision. Participation lasts for several months and involves regular check-ups.
This trial tests a new medication called IBI311 for people whose thyroid eye disease is no longer active but still causes bulging eyes. It aims to see if the drug can reduce eye bulging safely.
This early-stage trial tests a new drug called IBI3031 to treat active thyroid eye disease (TED), a condition where the immune system attacks muscles and tissue around the eyes, causing swelling, bulging, and sometimes double vision. The study aims to see if this drug can reduce inflammation and improve symptoms.
Hear when a new Graves Orbitopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.